Sugi Predict

Sugi Predict / Targets / BRAP

BRAP

BRCA1-associated protein · Q7Z569 · BRAP on Sugi Atlas →

7 patent compounds predicted against BRAP, 2 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6975177 SCHEMBL6975177 0.43 1/20
SCHEMBL15817526 SCHEMBL15817526 0.41 1/20

Clinical trials — most relevant to BRAP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. PHASE3COMPLETED
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations PHASE3WITHDRAWN
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy PHASE3COMPLETED
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy PHASE2COMPLETED
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer PHASE2UNKNOWN
Efficacy and Safety of PARPi to Treat Pancreatic Cancer PHASE2COMPLETED
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation PHASE2RECRUITING
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency PHASE2RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases PHASE2COMPLETED
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) PHASE2NOT_YET_RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer PHASE1COMPLETED
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations PHASE1UNKNOWN
Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer nanCOMPLETED
Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families nanCOMPLETED
Efficacy and Adverse Effects of Niraparib in Ovarian Cancer. nanUNKNOWN
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
Genetics of Prostate Cancer in Young Patients nanCOMPLETED
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment nanCOMPLETED
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients nanACTIVE_NOT_RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. nanUNKNOWN
Adherence to Intensive Surveillance for Hereditary Breast Cancer nanCOMPLETED
Testing a Culturally Adapted Telephone Genetic Counseling Intervention nanCOMPLETED
Endocrine Disruptors and Life STILe in Breast Cancer Development nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BRAP binder may also engage these)

ProteinNameSimilarity
Q99MP8 — 1.000 Q99MP8 →
Q8N1G2 — 0.985 Q8N1G2 →
Q15326 — 0.984 Q15326 →
Q9DBC3 — 0.984 Q9DBC3 →
Q05090 — 0.984 Q05090 →
Q95K79 — 0.983 Q95K79 →
Q5ZLG3 — 0.983 Q5ZLG3 →
Q5R5R4 — 0.983 Q5R5R4 →
Q9YHB5 — 0.983 Q9YHB5 →
A8WE67 — 0.983 A8WE67 →
Q8C5W4 — 0.983 Q8C5W4 →
Q5R981 — 0.983 Q5R981 →
Q96BT7 — 0.983 Q96BT7 →
Q84RR0 — 0.982 Q84RR0 →
Q6DFJ6 — 0.982 Q6DFJ6 →
Q6GL65 — 0.982 Q6GL65 →
Q6PGY6 — 0.982 Q6PGY6 →
B3M1E1 — 0.982 B3M1E1 →
Q8BXR9 — 0.982 Q8BXR9 →
Q14CX7 — 0.982 Q14CX7 →
Q8K4M9 — 0.981 Q8K4M9 →
Q8BWZ3 — 0.981 Q8BWZ3 →
Q9D8Y8 — 0.981 Q9D8Y8 →
A2AF47 — 0.981 A2AF47 →
Q6DHL7 — 0.981 Q6DHL7 →
Q9BZF3 — 0.981 Q9BZF3 →
F1QLY4 — 0.981 F1QLY4 →
A7Z061 — 0.981 A7Z061 →
Q9CXF4 — 0.981 Q9CXF4 →
Q96FV9 — 0.981 Q96FV9 →